Versartis Stock Price, News & Analysis (NASDAQ:VSAR)

$1.70 0.00 (0.00 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$1.70
Today's Range$1.65 - $1.75
52-Week Range$1.60 - $24.00
Volume707,975 shs
Average Volume579,550 shs
Market Capitalization$60.88 million
P/E Ratio-0.43
Dividend YieldN/A
Beta2.11

About Versartis (NASDAQ:VSAR)

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:VSAR
CUSIPN/A
Phone+1-650-9638580

Debt

Debt-to-Equity Ratio0.11%
Current Ratio1.52%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E Ratio-0.433673469387755
Forward P/E Ratio-0.41
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.34 per share
Price / Book0.39

Profitability

Trailing EPS($3.92)
Net Income$-95,810,000.00
Net MarginsN/A
Return on Equity-131.09%
Return on Assets-79.18%

Miscellaneous

Employees59
Outstanding Shares35,810,000

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) announced its earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.78. During the same period in the previous year, the company posted ($0.92) EPS. View Versartis' Earnings History.

When will Versartis make its next earnings announcement?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Versartis.

Where is Versartis' stock going? Where will Versartis' stock price be in 2018?

9 Wall Street analysts have issued 1-year price objectives for Versartis' stock. Their forecasts range from $3.00 to $14.00. On average, they anticipate Versartis' stock price to reach $5.63 in the next year. View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:

  • Srinivas Akkaraju M.D. Ph.D., Independent Chairman of the Board (Age 49)
  • Jay P. Shepard, President, Chief Executive Officer, Principal Financial Officer, Director (Age 59)
  • Shane M. Ward, Senior Vice President, General Counsel (Age 42)
  • Jay P. Stout, Senior Vice President, Technical Operations (Age 55)
  • Kevin Haas, Principal Accounting Officer, Vice President - Finance (Age 52)
  • Robert Gut M.D., Ph.D., Chief Medical Officer
  • Paul Westberg, Chief Business Officer (Age 49)
  • Tracy M. Woody, Chief Commercial Officer (Age 46)
  • Eric L. Dobmeier, Director (Age 48)
  • R. Scott Greer, Independent Director (Age 58)

Who owns Versartis stock?

Versartis' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.66%), Perceptive Advisors LLC (4.16%), Sabby Management LLC (2.77%), Guggenheim Capital LLC (2.53%), Ascend Capital LLC (1.74%) and Millennium Management LLC (1.50%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward and Srinivas Akkaraju. View Institutional Ownership Trends for Versartis.

Who sold Versartis stock? Who is selling Versartis stock?

Versartis' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Millennium Management LLC, TIAA CREF Investment Management LLC, Schwab Charles Investment Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Versartis company stock in the last year include Colin Hislop, Jay Shepard, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Shahzad Malik and Shane Ward. View Insider Buying and Selling for Versartis.

Who bought Versartis stock? Who is buying Versartis stock?

Versartis' stock was acquired by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, Two Sigma Investments LP, Sabby Management LLC, Goldman Sachs Group Inc., Anson Funds Management LP, Virtu Financial LLC, Ascend Capital LLC and Two Sigma Advisers LP. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy Versartis stock?

Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of Versartis stock can currently be purchased for approximately $1.70.

How big of a company is Versartis?

Versartis has a market capitalization of $60.88 million. The biopharmaceutical company earns $-95,810,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Versartis employs 59 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 4200 Bohannon Dr Ste 250, MENLO PARK, CA 94025-1021, United States. The biopharmaceutical company can be reached via phone at +1-650-9638580 or via email at [email protected]


MarketBeat Community Rating for Versartis (VSAR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Versartis (NASDAQ:VSAR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.222.222.303.00
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.63$5.63$7.22$26.83
Price Target Upside: 196.05% upside196.05% upside280.12% upside44.65% upside

Versartis (NASDAQ:VSAR) Consensus Price Target History

Price Target History for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ:VSAR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Cantor FitzgeraldSet Price TargetBuy$14.00N/AView Rating Details
9/25/2017Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
9/25/2017CitigroupDowngradeBuy -> Neutral$23.00 -> $3.00HighView Rating Details
9/22/2017Canaccord GenuityReiterated RatingBuy$28.00 -> $9.00N/AView Rating Details
9/22/2017Morgan StanleyReiterated RatingEqual Weight$3.00 -> $4.00N/AView Rating Details
9/22/2017SunTrust BanksDowngradeBuy -> Hold$25.00 -> $4.00N/AView Rating Details
9/22/2017CowenDowngradeOutperform -> Market Perform$45.00 -> $3.00N/AView Rating Details
9/22/2017BarclaysDowngradeOverweight -> Equal Weight$28.00 -> $4.00N/AView Rating Details
9/22/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$26.00 -> $4.00N/AView Rating Details
12/20/2016Credit Suisse GroupUpgradeNeutral -> Outperform$11.00 -> $20.00N/AView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformN/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Versartis (NASDAQ:VSAR) Earnings History and Estimates Chart

Earnings by Quarter for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ VSAR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.97)N/AView Earnings Details
10/26/2017Q3 2017($0.62)($1.40)ViewN/AView Earnings Details
7/27/2017Q2 2017($0.84)($1.04)ViewN/AView Earnings Details
4/27/2017Q1 2017($0.71)($0.85)ViewN/AView Earnings Details
2/21/2017Q4 2016($0.62)($0.64)$10.00 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.81)($0.92)ViewN/AView Earnings Details
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
4/28/2016Q1 2016($0.72)($0.82)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
8/5/2014Q2 2014($0.36)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Versartis (NASDAQ:VSAR) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.16 EPS
Next Year EPS Consensus Estimate: $-2.14 EPS

Dividends

Dividend History for Versartis (NASDAQ:VSAR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Versartis (NASDAQ VSAR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 48.73%
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ VSAR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Jay ShepardInsiderSell14,446$1.80$26,002.80602,298View SEC Filing  
2/8/2018Kevin HaasVPSell1,599$1.80$2,878.2078,218View SEC Filing  
2/8/2018Paul WestbergSVPSell5,355$1.80$9,639.00225,736View SEC Filing  
12/4/2017Srinivas AkkarajuDirectorBuy513,872$2.21$1,135,657.1214,955View SEC Filing  
12/1/2017Srinivas AkkarajuDirectorBuy419,700$2.13$893,961.0014,955View SEC Filing  
10/19/2017Colin HislopInsiderSell667$2.55$1,700.8523,833View SEC Filing  
10/19/2017Joshua T BrummCFOSell1,326$2.55$3,381.30201,269View SEC Filing  
10/19/2017Shane WardSVPSell776$2.55$1,978.8092,574View SEC Filing  
9/22/2017Life Sciences Maste PerceptiveMajor ShareholderSell2,130,000$3.29$7,007,700.00View SEC Filing  
6/13/2017Joshua T BrummCFOSell1,421$16.05$22,807.05105,595View SEC Filing  
6/13/2017Paul WestbergSVPSell711$16.05$11,411.5567,517View SEC Filing  
5/16/2017Joshua T. BrummCFOSell1,263$17.40$21,976.20View SEC Filing  
4/19/2017Paul WestbergSVPSell1,316$19.85$26,122.6068,228View SEC Filing  
4/4/2017Colin HislopInsiderSell35,000$21.20$742,000.0059,500View SEC Filing  
3/24/2017Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.2511,475View SEC Filing  
3/17/2017Shahzad MalikDirectorSell483,670$18.11$8,759,263.709,200View SEC Filing  
3/15/2017Shahzad MalikDirectorSell166,330$19.09$3,175,239.709,200View SEC Filing  
3/15/2017Shane WardSVPSell2,041$19.01$38,799.4137,126View SEC Filing  
2/27/2017Jay ShepardInsiderSell5,166$24.00$123,984.00219,024View SEC Filing  
2/27/2017Paul WestbergSVPSell12,500$22.50$281,250.0077,053View SEC Filing  
2/23/2017Jay ShepardInsiderSell16,000$19.25$308,000.00221,858View SEC Filing  
2/23/2017Paul WestbergSVPSell25,000$18.75$468,750.0087,954View SEC Filing  
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11213,858View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47234,046View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40220,058View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25108,724View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.6071,460View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.4446,912View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.5846,912View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.0846,912View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.5064,824View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.8544,600View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.0049,961View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.007,700View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.2565,814View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.2511,475View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.007,600View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96155,358View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.2458,835View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.7534,961View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.5560,283View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.4035,686View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.6035,548View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.2820,216View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.0036,538View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.0025,075View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Versartis (NASDAQ VSAR) News Headlines

Source:
DateHeadline
Versartis (VSAR) Set to Announce Quarterly Earnings on WednesdayVersartis (VSAR) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:40 AM
Insider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of StockInsider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of Stock
www.americanbankingnews.com - February 12 at 7:08 PM
BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis IncBRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc
www.reuters.com - February 8 at 8:12 AM
Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?
finance.yahoo.com - February 5 at 9:40 AM
Versartis Inc (VSAR) Given Consensus Rating of "Hold" by AnalystsVersartis Inc (VSAR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 2 at 5:46 AM
Zacks Investment Research Downgrades Versartis (VSAR) to SellZacks Investment Research Downgrades Versartis (VSAR) to Sell
www.americanbankingnews.com - January 21 at 8:42 AM
Zacks: Analysts Expect Versartis, Inc. (VSAR) Will Post Earnings of -$1.05 Per ShareZacks: Analysts Expect Versartis, Inc. (VSAR) Will Post Earnings of -$1.05 Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
Versartis, Inc. (VSAR) Receives Average Recommendation of "Hold" from AnalystsVersartis, Inc. (VSAR) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 8 at 3:54 AM
Exelixis (EXEL) & Versartis (VSAR) Financial AnalysisExelixis (EXEL) & Versartis (VSAR) Financial Analysis
www.americanbankingnews.com - December 25 at 3:24 PM
Versartis, Inc. (VSAR) Given Average Recommendation of "Hold" by AnalystsVersartis, Inc. (VSAR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 3:30 AM
-$0.98 EPS Expected for Versartis, Inc. (VSAR) This Quarter-$0.98 EPS Expected for Versartis, Inc. (VSAR) This Quarter
www.americanbankingnews.com - December 13 at 9:16 PM
Srinivas Akkaraju Buys 419,700 Shares of Versartis, Inc. (VSAR) StockSrinivas Akkaraju Buys 419,700 Shares of Versartis, Inc. (VSAR) Stock
www.americanbankingnews.com - December 5 at 8:58 PM
Insider Buying: Versartis, Inc. (VSAR) Director Buys 513,872 Shares of StockInsider Buying: Versartis, Inc. (VSAR) Director Buys 513,872 Shares of Stock
www.americanbankingnews.com - December 5 at 8:34 PM
Analyzing pSivida (PSDV) and Versartis (VSAR)Analyzing pSivida (PSDV) and Versartis (VSAR)
www.americanbankingnews.com - December 1 at 5:40 AM
 Brokerages Expect Versartis, Inc. (VSAR) Will Announce Earnings of -$0.98 Per Share Brokerages Expect Versartis, Inc. (VSAR) Will Announce Earnings of -$0.98 Per Share
www.americanbankingnews.com - November 25 at 11:26 PM
Versartis, Inc. (VSAR) Receives Average Rating of "Hold" from AnalystsVersartis, Inc. (VSAR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 19 at 6:16 AM
Versartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per ShareVersartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per Share
www.americanbankingnews.com - November 7 at 5:32 AM
Cantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price TargetCantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price Target
www.americanbankingnews.com - October 28 at 11:10 AM
Versartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic Transactions
www.streetinsider.com - October 28 at 8:25 AM
Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateVersartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - October 28 at 8:25 AM
Versartis Hires Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions
finance.yahoo.com - October 28 at 8:25 AM
Versartis, Inc. (VSAR) Posts Quarterly  Earnings Results, Misses Expectations By $0.78 EPSVersartis, Inc. (VSAR) Posts Quarterly Earnings Results, Misses Expectations By $0.78 EPS
www.americanbankingnews.com - October 27 at 3:40 PM
Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - October 27 at 3:06 AM
Versartis, Inc. (VSAR) Given Average Rating of "Hold" by AnalystsVersartis, Inc. (VSAR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 25 at 7:34 AM
Versartis, Inc. (VSAR) Set to Announce Quarterly Earnings on WednesdayVersartis, Inc. (VSAR) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Zacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per ShareZacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - October 18 at 12:28 PM
Versartis, Inc. (VSAR) Sees Large Increase in Short InterestVersartis, Inc. (VSAR) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 13 at 1:58 AM
Versartis, Inc. (VSAR) Receives Consensus Recommendation of "Hold" from BrokeragesVersartis, Inc. (VSAR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 30 at 6:44 AM
Versartis, Inc. (VSAR) Expected to Announce Earnings of -$0.68 Per ShareVersartis, Inc. (VSAR) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - September 29 at 6:22 PM
FY2017 Earnings Estimate for Versartis, Inc. (VSAR) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Versartis, Inc. (VSAR) Issued By Cantor Fitzgerald
www.americanbankingnews.com - September 28 at 7:52 AM
Insider Selling: Versartis, Inc. (VSAR) Major Shareholder Sells 2,130,000 Shares of StockInsider Selling: Versartis, Inc. (VSAR) Major Shareholder Sells 2,130,000 Shares of Stock
www.americanbankingnews.com - September 25 at 7:14 PM
Bank of America Corporation Downgrades Versartis, Inc. (VSAR) to NeutralBank of America Corporation Downgrades Versartis, Inc. (VSAR) to Neutral
www.americanbankingnews.com - September 25 at 12:52 PM
Is Versartis Inc (VSAR) Undervalued?Is Versartis Inc (VSAR) Undervalued?
finance.yahoo.com - September 23 at 10:53 AM
Human Growth Drug Flop Sends This Biotech Crashing 83%Human Growth Drug Flop Sends This Biotech Crashing 83%
finance.yahoo.com - September 23 at 10:53 AM
Ascendis Pharma shares surge 42% on competitors flopAscendis Pharma shares surge 42% on competitor's flop
finance.yahoo.com - September 23 at 10:53 AM
Versartis Inc. (VSAR) Is Plummeting After Phase 3 Study FailedVersartis Inc. (VSAR) Is Plummeting After Phase 3 Study Failed
www.rttnews.com - September 23 at 10:53 AM
Versartis shares down 82%Versartis shares down 82%
www.marketwatch.com - September 23 at 10:53 AM
Versartis, Inc. (VSAR) PT Lowered to $9.00 at Canaccord GenuityVersartis, Inc. (VSAR) PT Lowered to $9.00 at Canaccord Genuity
www.americanbankingnews.com - September 22 at 3:14 PM
Versartis, Inc. (VSAR) Downgraded to Neutral at Piper Jaffray CompaniesVersartis, Inc. (VSAR) Downgraded to Neutral at Piper Jaffray Companies
www.americanbankingnews.com - September 22 at 12:40 PM
Versartis, Inc. (VSAR) Lowered to Underweight at Barclays PLCVersartis, Inc. (VSAR) Lowered to Underweight at Barclays PLC
www.americanbankingnews.com - September 22 at 12:40 PM
Cowen and Company Downgrades Versartis, Inc. (VSAR) to Market PerformCowen and Company Downgrades Versartis, Inc. (VSAR) to Market Perform
www.americanbankingnews.com - September 22 at 11:58 AM
Versartis, Inc. (VSAR) Stock Rating Lowered by SunTrust Banks, Inc.Versartis, Inc. (VSAR) Stock Rating Lowered by SunTrust Banks, Inc.
www.americanbankingnews.com - September 22 at 9:18 AM
Versartis, Inc. (VSAR) Earns "Equal Weight" Rating from Morgan StanleyVersartis, Inc. (VSAR) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - September 22 at 9:18 AM
Versartis, Inc. (VSAR) PT Lowered to $14.00Versartis, Inc. (VSAR) PT Lowered to $14.00
www.americanbankingnews.com - September 22 at 9:18 AM
Notable Thursday Option Activity: VMC, LGIH, VSARNotable Thursday Option Activity: VMC, LGIH, VSAR
www.thestreet.com - September 15 at 11:15 AM
Financial Contrast: Versartis (VSAR) versus its PeersFinancial Contrast: Versartis (VSAR) versus its Peers
www.americanbankingnews.com - September 11 at 1:06 PM
Versartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray CompaniesVersartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - September 8 at 6:44 PM
Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017
finance.yahoo.com - September 8 at 10:07 AM
Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory AffairsVersartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs
finance.yahoo.com - September 6 at 10:04 AM
Versartis, Inc. (VSAR) Given Consensus Recommendation of "Buy" by BrokeragesVersartis, Inc. (VSAR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 6:28 AM

SEC Filings

Versartis (NASDAQ:VSAR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Versartis (NASDAQ:VSAR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Versartis (NASDAQ VSAR) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.